

Appendix Table F30. Continence after topical estrogen treatment compared to no active treatment (individual RCTs)

Reference N	Active	Definition of continence	Randomized active/control	Active events/rate	Control events/rate	Relative risk (95% CI)	Absolute risk differences (95% CI)	Number needed to treat (95% CI)	Attributable events/1,000 treated (95% CI)
Holtedahl, 1998 ³⁰⁸ 80	Local estrogen in tablets or jelly plus physiotherapy and electro stimulation	Number of cured: no reported leakage and no wet episodes	36/44	8/22	0/0	20.68 (1.23; 346.46)	0.22 (0.08; 0.36)	5 (3; 12)	222 (83; 361)
Rufford, 2003 ³⁷⁰ 40	25 mg 17 beta-estradiol implant	Urgency, % of cured	20/20	3/15	2/10	1.50 (0.28; 8.04)	0.05 (-0.15; 0.25)		
Rufford, 2003 ³⁷⁰ 40	25 mg 17 beta-estradiol implant	Stress incontinence, % cured	20/20	4/20	3/15	1.33 (0.34; 5.21)	0.05 (-0.18; 0.28)		
Rufford, 2003 ³⁷⁰ 40	25 mg 17 beta-estradiol implant	Dysuria, % of cured	20/20	4/20	3/15	1.33 (0.34; 5.21)	0.05 (-0.18; 0.28)		
Rufford, 2003 ³⁷⁰ 40	25 mg 17 beta-estradiol implant	Urge incontinence, % of cured	20/20	7/35	6/30	1.17 (0.48; 2.86)	0.05 (-0.24; 0.34)		